Thu, Jul 24, 2014, 10:02 AM EDT - U.S. Markets close in 5 hrs 58 mins

Recent

% | $
Click the to save as a favorite.

Amarantus Bioscience Holdings, Inc Message Board

  • fence4u2 fence4u2 Sep 13, 2013 11:19 AM Flag

    Amarantus Appoints F. Randall Grimes, MBA as Director of Sponsored Research

    SUNNYVALE, Calif., Sep 13, 2013 (GLOBE NEWSWIRE via COMTEX) -- Amarantus
    Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the
    discovery and development of novel diagnostics and therapeutics related to
    neurodegeneration and apoptosis, today announced that it has appointed Mr. F.
    Randall Grimes, MBA as Director of Sponsored Research. Mr. Grimes will be
    focused on working with Amarantus' scientific team, Board of Advisors and
    outside collaborators to support the acquisition of non-dilutive funding from
    disease foundations, non-governmental and governmental organizations to advance
    Amarantus' pipeline.

    "As we have now secured funding to allow the Company to operate well into 2014,
    we are in a good position to gain access to non-dilutive forms of funding to
    advance our pipeline in a number of key areas," said Gerald E. Commissiong,
    President & CEO of Amarantus. "Mr. Grimes' previous experience in gaining over
    $1.5 million in National Institutes of Health grants for LymPro will ultimately
    prove to be invaluable as we now have intimate access to historical knowledge
    that will guide our future sponsored research program in the LymPro program.
    Going forward for MANF, we intend to significantly leverage non-dilutive funding
    to support MANF product development, especially in secondary programs that will
    result from the reprioritizing process that we are currently conducting as a
    result of positive data in orphan indications that has begun to flow in from
    studies underway. We believe there is a significant appetite among certain
    disease foundations to support MANF development due to data that has already
    been generated, and given that we own the composition of matter patents and are
    moving forward in a product development program, we are in an excellent position
    to collaborate with the various researchers that have begun to publish on MANF.
    Having Mr. Grimes on in-house to coordinate the drafting and processing of grant
    applications will only serve to further help the Company leverage those
    resources."

    Mr. F. Randall Grimes has more than 20 years of marketing, business development,
    financial and R&D leadership experience in early stage life science companies.
    He founded The Randall Group in 2001 to help small to medium-sized technology
    companies raise funds using state and federal competitive grants. He has
    garnered over $25 million in non-dilutive capital for clients and employers,
    including more than $1.5 million for LymPro Test development. Mr. Grimes has
    previously served as the Vice President of Technology Development at Provista
    Diagnostics, Inc., Vice President of Operations at RCP Diagnostics, Biomarker
    Technologies LLC and GW Medical Technologies LLC. Mr. Grimes has authored eight
    issued patents and has published articles in major technical and trade journals.
    He holds a B.S from University of Arizona in Material Sciences and Engineering
    and M.B.A from University of Michigan Business School with an emphasis in new
    product development, marketing and operations management.

    "I am extremely pleased to be joining Amarantus at this juncture. Having been
    involved with the LymPro program for almost a decade, it is extremely gratifying
    to see the program making great strides, not only in terms of product
    development with Becton Dickinson, but also in terms of getting into the
    mainstream of Alzheimer's disease research with the recent evidence emerging
    linking abhorrent cell-cycle re-entry to amyloid beta and tau," said Mr. Grimes.
    "We began the process of drafting grants for Amarantus over the summer, and will
    begin now aggressively pursuing a sponsored research agenda heading into the
    fall given various data sets and delivery arrangements emerging for MANF in a
    number of therapeutic areas."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Two important points:

      1. As we have now secured funding to allow the Company to operate well into 2014,
      we are in a good position to gain access to non-dilutive forms of funding to
      advance our pipeline in a number of key areas," said Gerald E. Commissiong,
      President & CEO of Amarantus.

      2. "I am extremely pleased to be joining Amarantus at this juncture. Having been
      involved with the LymPro program for almost a decade, it is extremely gratifying
      to see the program making great strides, not only in terms of product
      development with Becton Dickinson, but also in terms of getting into the
      mainstream of Alzheimer's disease research with the recent evidence emerging
      linking abhorrent cell-cycle re-entry to amyloid beta and tau," said Mr. Grimes.
      "We began the process of drafting grants for Amarantus over the summer, and will
      begin now aggressively pursuing a sponsored research agenda heading into the
      fall given various data sets and delivery arrangements emerging for MANF in a
      number of therapeutic areas."

      • 1 Reply to smittysamigo
      • Agree, if as many believe, we will get solid news on BD position soon an important milestone will have been reached. (IMO)...Again, positve mention of BD, very important business point. "it is extremely gratifying
        to see the program making great strides, not only in terms of product
        development with Becton Dickinson, but also in terms of getting into the
        mainstream of Alzheimer's disease research with the recent evidence emerging
        linking abhorrent cell-cycle re-entry to amyloid beta and tau,"

 
AMBS
0.1480.000(0.00%)9:32 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.